The tumor-suppressive function of BAP1 has been further supported by antagonizing the activity of the ERK1/2 signaling pathway with the U0126 inhibitor, which reduced iCCA cell proliferation, cell cycle progression, and invasion [88]. Here, PRRT2 is linked to neoplasm.